The drugmakers pledged to invest $19.6 billion collectively in U.S. manufacturing and provide discounts on select medicines in exchange for tariff exemptions.
The Santiago facility received EXCiPACT certification for pharmaceutical excipient manufacturing covering commercial-scale QS-21 and other saponin fractions.